In a high-burden TB and HIV setting, the availability of AlereLAM at ambulatory level meant that more patients with both HIV and TB who were presenting for care with low CD4 counts were initiated on TB treatment on the same day as presentation, and the proportion initiating TB treatment empirically was nearly halved. The gene discussed is CD4; the disease is tuberculosis.